Clinical Trial Details


Research Study Summary

A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease


The aim of this clinical study is to investigate the efficacy and safety of laquinimod as a potential treatment for patients with Huntington’s disease. This study is being conducted to determine if laquinimod helps with the signs and symptoms of Huntington’s disease after 12 months of treatment.

To Learn more

CW ID: 213450
Date Last Changed: February 15, 2017

Clinical Trial Snapshot

Both Male and Female
21 to 55 Years
Overall Status
Lead Sponsor
Facility Type


Inclusion Criteria:

  • Positive genetic testing for HD, or a clinical diagnosis of symptomatic HD (Diagnostic Confidence Level 4)
  • Presence of 36-49 CAG repeats, inclusive, in the huntingtin gene based on centralized CAG testing during screening
  • Male or female between 21-55 years of age, inclusive, with an onset of HD at or after 18 years of age
  • A sum of >5 points on the UHDRS-TMS at the screening visit
  • UHDRS-TFC ≥ 8 at the screening visit
  • Ambulatory, being able to travel to the study center, and judged by the investigator as likely to be able to continue to travel for the duration of the study
  • Availability and willingness of a caregiver, informant, or family member to provide input at study visits assessing CIBIC-Plus, CDR-SB, PBA-s and HD-QoL

Exclusion Criteria:

  • Use of immunosuppressive agents, or cytotoxic agents, including cyclophosphamide and azathioprine within 12 months prior to screening
  • Previous use of laquinimod
  • Pregnant or breastfeeding
  • Subjects with a clinically significant or unstable medical or surgical condition


Kelly Elliott
University of South Florida -Morsani Center for Advanced Healthcare
13330 USF Laurel Drive
Tampa, FL 33612
Phone: 813-974-6022

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.